ABSTRACT
Background: Gestational hypertension and preeclampsia is one of the leading causes of maternal and fetal morbidity and mortality. The objective of this study was to study prediction of gestational hypertension/preeclampsia by using first trimester serum vitamin D and hs-CRP and second trimester uterine artery diastolic notching.Methods: It was an observational study conducted in the departments of obstetrics and gynaecology, clinical biochemistry and radiology, Vardhman Mahavir Medical College and Safdarjung Hospital, New Delhi, India. All pregnant women with 11 to 14 weeks gestational age attending antenatal clinic between October 2012 and June 2013 were enrolled in the study. A detailed history including history of the duration of sun exposure was taken and a general physical examination including obstetrical examination was done at every visit. Serum sample were taken for hs-CRP and vitamin-D levels at 11-14 weeks. Uterine artery colour doppler study was done between 22-24 weeks for uterine artery diastolic notching. The main outcome measures were development of gestational hypertension/ preeclampsia/ eclampsia.Results: The mean vitamin D levels were significantly lower and mean hs-CRP levels were significantly higher in the hypertensive group as compared to the normotensive group, p=0.001 and p=0.004, respectively. Significant number women who developed hypertension had unilateral (46.2%) or bilateral (20.4%) uterine artery diastolic notching, p=0.005 and p=0.000, respectively. Crude’s odds ratio of uterine artery diastolic notching for prediction of hypertension in pregnancy was high, 9.894, 95% CI, 3.273-29.907 as compared to vitamin D (<13.5 ng/ml) and hs-CRP (>9.15 mg/L), 2.859, 95% CI, 1.418-5.763 and 7.16, 95% CI, 3.33-15.397.Conclusions: Uterine artery diastolic notching in the early second trimester is found to be the best predictor of PE followed by first trimester hs-CRP and vitamin D.
ABSTRACT
Objective To investigate the correlation of serum(SF)and hepcidin(Hepc)level with cardi-ac function and chronic heart failure(CHF).Methods A total of 80 elderly patients with CHF who had received treatment in our hospital from October 2015 to February 2017 were assigned to CHF group and 80 patients without heart failure were assigned to a control group. Serum SF and hepidin levels in both the groups were measured and compared.Results Serum hepidin and hs-C-reactive protein levels were all significantly higher in CHF group than in the control group[(69.58 ± 27.16)ng/ml vs.(128.46 ± 33.28)ng/mL;(97.16 ± 16.81)ng/mL vs.(54.12 ± 15.76)ng/mL;(3.3 ± 1.64)mg/L vs.(2.78 ± 1.36)mg/L].Multiple logistic regression analysis showed that SF was an independent protective factor for CHF(P < 0.05);Hepc and hs-CRP were independent risk factors for CHF (P<0.05).Conclusions Serum hepcidin and hs-C-reactive protein may be risk factors for chronic heart failure. Measurement of serum hepidin and hs-CRP levels is helpful for early prevention and treatment of heart failure.
ABSTRACT
Plasma C-reactive protein (CRP) concentrations are increased in obese individuals. In this study, we examined the correlation between hsCRP and left ventricular mass (LV mass). Fourty five healthy obese women and fourty five healthy non obese women as the controls group were studied by echocardiography and hsCRP. There was no significant correlation between hsCRP and left ventricular mass in obese women (r = 0.29, p 0.06). There was a significant correlation between hs CRP and body mass index (r = 0.46, p 0,002), and also hsCRP and visceral fat (r= 0.33, p 0.03).
Subject(s)
Obesity , WomenABSTRACT
Objective To investigate the relationship between the hs-c-reactive protein and the severity of coronary artery disease.Methods All the 67 patients underwent coronary angiography and measured risk factors,the Gensini score was used to determine the results of the coronary angiography.The t test,One-Way ANOVA and multiple linear regression analysis were used to predict hs-CRP.Results Coronary artery disease group hs-CRP levels were significantly higher than those in non-coronary artery disease group(P